Sage Therapeutics Inc logo

Sage Therapeutics Inc

2
NAS:SAGE (USA)  
$ 22.48 +0.47 (+2.14%) 01:44 PM EST
At Loss
P/B:
1.65
Enterprise V:
$ 574.93M
Volume:
330.31K
Avg Vol (2M):
994.29K
Also Trade In:
Volume:
330.31K
At Loss
Avg Vol (2M):
994.29K

Business Description

Sage Therapeutics Inc logo
Sage Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US78667J1088
Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Name Current Vs Industry Vs History
Cash-To-Debt 145.83
Equity-to-Asset 0.91
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.66
Distress
Grey
Safe
Beneish M-Score 6.65
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.28
9-Day RSI 33.77
14-Day RSI 38.6
6-1 Month Momentum % 35.24
12-1 Month Momentum % -35.79

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.51
Quick Ratio 10.51
Cash Ratio 9.1
Days Payable 2093.68

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1
Shareholder Yield % 0.51

Financials (Next Earnings Date:2024-05-02 Est.)

SAGE's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:SAGE

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Sage Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 86.456
EPS (TTM) ($) -9.05
Beta 0.36
Volatility % 59.81
14-Day RSI 38.6
14-Day ATR ($) 1.28635
20-Day SMA ($) 24.274
12-1 Month Momentum % -35.79
52-Week Range ($) 16.515 - 59.99
Shares Outstanding (Mil) 60.11

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Sage Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Sage Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Sage Therapeutics Inc Frequently Asked Questions

What is Sage Therapeutics Inc(SAGE)'s stock price today?
The current price of SAGE is $22.48. The 52 week high of SAGE is $59.99 and 52 week low is $16.52.
When is next earnings date of Sage Therapeutics Inc(SAGE)?
The next earnings date of Sage Therapeutics Inc(SAGE) is 2024-05-02 Est..
Does Sage Therapeutics Inc(SAGE) pay dividends? If so, how much?
Sage Therapeutics Inc(SAGE) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1